The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1502
August 29, 2016
View Complete Issue         Table of Contents 2019 
Lifitegrast (Xiidra) for Dry Eye Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lifitegrast (Xiidra) for Dry Eye Disease
August 29, 2016 (Issue: 1502)
The FDA has approved a 5% ophthalmic solution of lifitegrast (Xiidra – Shire), a lymphocyte function-associated antigen-1 (LFA-1) antagonist, for treatment of the signs and symptoms of dry eye disease. Lifitegrast is the first LFA-1 antagonist...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lifitegrast (Xiidra) for Dry Eye Disease
Article code: 1502b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.